Description: Votrient is a medication containing the active ingredient pazopanib. Pazopanib belongs to a class of drugs known as tyrosine kinase inhibitors. It is used in the treatment of advanced renal cell carcinoma (kidney cancer), certain types of soft tissue sarcoma (STS), and advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Indications: Votrient is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults who have received prior cytokine therapy. It is also used for the treatment of advanced or metastatic STS in patients who have received prior chemotherapy. Additionally, Votrient is approved for the treatment of advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have received prior chemotherapy.

Mechanism of Action: Pazopanib works by inhibiting the activity of multiple protein kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. By blocking these pathways, pazopanib interferes with the growth and spread of cancer cells, ultimately inhibiting tumor angiogenesis (the formation of new blood vessels) and slowing down cancer progression.

Administration: Votrient is administered orally in the form of tablets. The recommended dose is typically taken once daily, with or without food. The dosage and duration of treatment may vary depending on the type and stage of cancer, as well as individual patient factors.

Side Effects: Common side effects of Votrient may include diarrhea, hypertension (high blood pressure), nausea, vomiting, fatigue, and hair color changes. Patients may also experience more serious side effects, such as liver toxicity, heart problems, or bleeding, and it’s important to promptly report any unusual symptoms to the healthcare provider.

Precautions: Patients receiving Votrient should be closely monitored for potential side effects, and regular blood tests are often conducted during treatment. It’s important for patients to inform their healthcare provider about any pre-existing conditions, medications, or supplements they may be taking, as these may interact with pazopanib.

Votrient is a targeted therapy that offers a treatment option for patients with certain types of advanced or metastatic cancer. As with any medication, specific details may vary, and patients should rely on the guidance of their healthcare provider for personalized information and advice.